Cost-effectiveness of genotyping to guide treatment

被引：0

作者：

Sorich, Michael J. ^{[1
]}

Wiese, Michael D. ^{[2
]}

Pekarsky, Brita ^{[3
]}

机构：

[1] Flinders Univ S Australia, Sch Med, Dept Clin Pharmacol, Adelaide, SA 5042, Australia

[2] Univ S Australia, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia

[3] Baker IDI Heart & Diabet Inst, Adelaide, SA, Australia

来源：

PHARMACOGENOMICS | 2014年 / 15卷 / 06期

关键词：

clinical translation; clinical utility; cost-effectiveness; evidence; pharmacogenetics; pharmacogenomics; prioritization; PERSONALIZED MEDICINE;

D O I：

10.2217/PGS.14.24

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：727 / 729

页数：3

共 15 条

[1] OUTLOOK The microeconomics of personalized medicine: today's challenge and tomorrow's promise
Davis, Jerel C.
Furstenthal, Laura
Desai, Amar A.
Norris, Troy
Sutaria, Saumya
Fleming, Edd
Ma, Philip
[J]. NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (04) : 279 - 286
[2] Pharmacogenomics, Evidence, and the Role of Payers
Deverka, R. A.
[J]. PUBLIC HEALTH GENOMICS, 2009, 12 (03) : 149 - 157
[3] Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore
Dong, Di
Sung, Cynthia
Finkelstein, Eric Andrew
[J]. NEUROLOGY, 2012, 79 (12) : 1259 - 1267
[4] The role of cost-effectiveness analysis in the era of pharmacogenomics
Flowers, CR
Veenstra, D
[J]. PHARMACOECONOMICS, 2004, 22 (08) : 481 - 493
[5] Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial
Grigor, C
Capell, H
Stirling, A
McMahon, AD
Lock, P
Vallance, R
Kincaid, W
Porter, D
[J]. LANCET, 2004, 364 (9430) : 263 - 269
[6] Methodological quality of pharmacogenetic studies: Issues of concern
Jorgensen, Andrea L.
Williamson, Paula R.
[J]. STATISTICS IN MEDICINE, 2008, 27 (30) : 6547 - 6569
[7] The Evidence Dilemma In Genomic Medicine
Khoury, Muin J.
Berg, Al
Coates, Ralph
Evans, James
Teutsch, Steven M.
Bradley, Linda A.
[J]. HEALTH AFFAIRS, 2008, 27 (06) : 1600 - 1611
[8] Personalized Medicine in Rheumatoid Arthritis: Miles to Go Before We Sleep
Plenge, Robert M.
Bridges, S. Louis, Jr.
[J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (03): : 590 - 593
[9] Forget personalised medicine and focus on abating disease activity
Smolen, Josef S.
Aletaha, Daniel
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (01) : 3 - 6
[10] Sorich MJ, 2013, PHARMACOGENOMICS, V14, P2013, DOI [10.2217/PGS.13.164, 10.2217/pgs.13.164]

← 1 2 →